Literature DB >> 18430472

EBV transformation overrides gene expression patterns of B cell differentiation stages.

Dörte Siemer1, Julia Kurth, Stephan Lang, Götz Lehnerdt, Jens Stanelle, Ralf Küppers.   

Abstract

EBV-associated Hodgkin lymphoma (HL) and some post-transplant lymphoproliferative disease (PTLD) cases originate from pro-apoptotic germinal center (GC) B cells that have acquired destructive somatic Ig V gene mutations and were presumably rescued from apoptosis by EBV. To find out whether B cell receptor-crippled GC B cells acquire features of HL and/or PTLD cells upon EBV-infection and to reveal the impact of EBV on expression of B cell differentiation markers, we compared lymphoblastoid cell lines (LCLs) from GC B cells (including BCR-crippled GC-LCLs) to monoclonal LCLs from naïve B cells (N-LCLs). In addition, we analyzed the controversially discussed effect of EBV-infection on the GC B-cell-specific process of somatic hypermutation in vitro. Irrespective of their cellular origin, LCLs expressed CD20, CD30, CD38, AID, Pu.1, and with one exception Syk, but lacked expression of the GC B cell marker BCL-6. Interestingly, the T cell transcription factor GATA-3 that is aberrantly expressed in HL was induced in most GC-LCLs and the memory B cell marker CD27 was activated in N-LCLs. Remarkably, only 4 of 24 GC-LCLs showed significant somatic hypermutation activity, demonstrating that EBV usually silences hypermutation upon infection of GC B cells. Notably, one of three N-LCL showed a low level of intraclonal diversification. Thus, EBV-infection deregulates multiple differentiation factors and processes in B cells, leading to a largely homogenous phenotype of EBV-infected B cells in latency III.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18430472     DOI: 10.1016/j.molimm.2008.03.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  22 in total

Review 1.  EBV Persistence--Introducing the Virus.

Authors:  David A Thorley-Lawson
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  A novel platform to produce human monoclonal antibodies: The next generation of therapeutic human monoclonal antibodies discovery.

Authors:  Marcus Duvall; Norma Bradley; Ryan N Fiorini
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

Review 3.  Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).

Authors:  Bradley M Haverkos; Carrie Coleman; Alejandro A Gru; Zenggang Pan; Jonathan Brammer; Rosemary Rochford; Anjali Mishra; Christopher C Oakes; Robert A Baiocchi; Aharon G Freud; Pierluigi Porcu
Journal:  Discov Med       Date:  2017-03       Impact factor: 2.970

Review 4.  Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.

Authors:  Margaret L Gulley; Weihua Tang
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

5.  Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis.

Authors:  S A Sargsyan; A J Shearer; A M Ritchie; M P Burgoon; S Anderson; B Hemmer; C Stadelmann; S Gattenlöhner; G P Owens; D Gilden; J L Bennett
Journal:  Neurology       Date:  2010-03-10       Impact factor: 9.910

6.  PU.1-dependent regulation of UCH L1 expression in B-lymphoma cells.

Authors:  Anjali Bheda; Wei Yue; Anuradha Gullapalli; Julia Shackelford; Joseph S Pagano
Journal:  Leuk Lymphoma       Date:  2011-04-20

Review 7.  The pathogenesis of Epstein-Barr virus persistent infection.

Authors:  David A Thorley-Lawson; Jared B Hawkins; Sean I Tracy; Michael Shapiro
Journal:  Curr Opin Virol       Date:  2013-05-15       Impact factor: 7.090

8.  Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ.

Authors:  Ebba Sohlberg; Shanie Saghafian-Hedengren; Eahsan Rasul; Giovanna Marchini; Caroline Nilsson; Eva Klein; Noémi Nagy; Eva Sverremark-Ekström
Journal:  J Immunol       Date:  2013-10-18       Impact factor: 5.422

Review 9.  The Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.

Authors:  A A Gru; B H Haverkos; A G Freud; J Hastings; N B Nowacki; C Barrionuevo; C E Vigil; R Rochford; Y Natkunam; R A Baiocchi; P Porcu
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

10.  Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients.

Authors:  Mikael Brisslert; Maria Rehnberg; Maria I Bokarewa
Journal:  Immunology       Date:  2013-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.